gms | German Medical Science

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2024)

22. - 25.10.2024, Berlin

The safety and efficacy of microporous polysaccharide hemospheres on the complications rate after total hip arthroplasty for femoral neck fractures

Meeting Abstract

  • presenting/speaker Olga Pidgaiska - Charité – Universitätsmedizin,CMSC, Berlin, Germany
  • Stavros Goumenos - Charité – Universitätsmedizin,CMSC, Berlin, Germany
  • Marcel Niemann - Charité – Universitätsmedizin,CMSC, Berlin, Germany
  • Andrej Trampuz - Charité – Universitätsmedizin,CMSC, Berlin, Germany
  • Ulrich Stöckle - Charité – Universitätsmedizin,CMSC, Berlin, Germany
  • Sebastian Meller - Charité – Universitätsmedizin,CMSC, Berlin, Germany

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2024). Berlin, 22.-25.10.2024. Düsseldorf: German Medical Science GMS Publishing House; 2024. DocAB91-2948

doi: 10.3205/24dkou525, urn:nbn:de:0183-24dkou5252

Veröffentlicht: 21. Oktober 2024

© 2024 Pidgaiska et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objectives: This study aimed to assess the safety and efficacy of microporous polysaccharide hemospheres (MPSHs) in managing blood loss and reducing the risk of postoperative haematoma and early periprosthetic joint infection (PJI) following total hip arthroplasty (THA) for femoral neck fracture (FNF), in the context of the existing treatment challenges.

Methods: A control-matched retrospective analysis of 163 patients undergoing unilateral primary THA for displaced FNF between 2020 and 2023 was performed. The study group consisted of 74 patients who received MPSH administered intraoperatively. The control group consisted of 89 patients who received no topical haemostatics. One-to-one case-control matching between groups was performed. The primary outcome was a perioperative change in the haematologic values (haemoglobin, red blood cell count, haematocrit, platelet concentration) and transfusion rate. The secondary outcomes were the incidence of postoperative local haematoma formation, prolonged wound secretion, surgical site infection (SSI), and PJI within 3 months of surgery.

Results: Our analysis found no statistically significant differences in the haematologic parameters between the control and study cohorts. The changes in the haemoglobin concentration were not significant between the control group (3.18 ± 1.0 g/dL) and the treatment group (2.87 ± 1.15 g/dL) (p = 0.3). There were no significant differences (p = 0.24) in the haematocrit and red blood cell concentration (p = 0.15). The platelet levels did not significantly differ (p = 0.12) between the groups. Additionally, we found no significant discrepancy in the incidence of early PJI or blood transfusion rates between the groups. No adverse effects following MPSH use were recorded in the study group.

Conclusion: Routine use of MPSH in THA for FNF management appears to be safe, with no observed adverse events related to Arista® use. Although there was a tendency towards reduced blood loss in the Arista® AH group, MPSH did not significantly impact bleeding complications, local haematoma formation, or subsequent PJI.